Imagine a world where a simple treatment could transform a child’s ability to see clearly, yet countless kids are denied access due to red tape and regulatory hurdles. This is the heartbreaking reality for American children with myopia, a condition that affects millions and can significantly impact their quality of life. As a pediatric ophthalmologist, I’ve witnessed firsthand the frustration of telling patients and their families that a proven treatment is out of reach—not because it’s ineffective, but because of systemic failures that prioritize bureaucracy over children’s well-being. But here’s where it gets controversial: while eyeglasses and contact lenses are widely accepted solutions, a drug that could potentially slow the progression of myopia remains caught in a regulatory limbo, leaving many to wonder: Are we failing our children by not making every effective option available?
Democracy Dies in Darkness, and in this case, so does the potential for clearer vision and brighter futures. American children with myopia deserve better than this regulatory failure. Let’s take a step back and reflect on the personal impact of this condition. I still remember the day I got my first pair of glasses at age 8. Walking out of the optical shop, I was stunned to see individual leaves on trees and blades of grass—details that had been nothing but blurry shapes moments before. That’s the power of correcting myopia, yet for many, even this basic clarity is a struggle. And this is the part most people miss: myopia isn’t just about blurry vision; if left unchecked, it can lead to serious eye conditions later in life, including glaucoma, cataracts, and retinal detachment. So, why are we not doing everything in our power to address it early?
As president of the American Association for Pediatric Ophthalmology and Strabismus, a professor of ophthalmology at Harvard Medical School, and co-founder of the medical device company Rebion, I’ve seen the potential of innovative treatments to change lives. Yet, the system often feels rigged against progress. Is it fair to let regulatory delays stand in the way of children’s eye health? I’d argue it’s not just unfair—it’s a moral failing. We owe it to the next generation to advocate for policies that prioritize their needs, not bureaucratic obstacles. What do you think? Is the current approach to myopia treatment sufficient, or is it time to demand more for our children? Let’s start the conversation—because every child deserves the chance to see the world with clarity.
